Description of the medicine: Candesartan (Candesartan)
(±) 1H-Benzimidazole-7-carboxylic acid 2-ethoxy-1 - [[2 '- (H-tetrazol-5-yl) [1,1'-biphenyl] 4-yl] methyl] -1 - [[ cyclohexyloxy] carbonyl] oxy] ethyl ether.
Synonym: Atacand, Atacand.
In structure (the presence of a tetrazolyl-phenyl-benzyl fragment) is similar to losartan.
Compared with losartan and valsartan, it is more active.
When administered, the bioavailability is about 40%, C max - 3-4 hours, T 9 - 9 hours; partially subjected to biotransformation in the liver, excreted mainly with bile.
Assign inside as an antihypertensive agent at 0.004-0.008 g (4-8 mg) 1 time per day.
The maximum antihypertensive effect usually develops 4 weeks after the start of treatment.
Side effects (headache, back and muscle pain, dizziness, nausea, impaired liver function tests) are rare.
Contraindications: severe liver dysfunction, cholestasis, breast-feeding.
Release form: tablets on 0,004; 0.008 and 0.016 g (4, 8 and 16 mg) (N. 14, 100).
Storage: List B.